Abstract 376P
Background
Optimal treatment outcomes in breast cancer heavily rely on patient adherence to oral anticancer medications (OAMs). This study investigates the differences in adherence rates between metastatic and non-metastatic breast cancer patients using a comprehensive dual-method approach.
Methods
In this cross-sectional study at the National Cancer Institute, Cairo University, 500 breast cancer patients were categorized into metastatic (45.6%) and non-metastatic (54.4%) groups. Adherence was measured using the Morisky Medication Adherence Scale (MMAS-8) and the Medication Possession Ratio (MPR), with nonadherence defined as an MMAS-8 score < 8 or an MPR < 80 %. Data collection was augmented by patient interviews and examination of outpatient pharmacy dispensing records.
Results
Adherence rates were 46.4% as per MMAS-8 and 71% according to MPR. Specifically, in the non-metastatic group, MMAS-8 revealed a 28.3% adherence rate, while MPR showed 75.4%. Metastatic patients displayed significantly higher adherence (p<0.001). There was a notable inverse correlation between adherence and the severity of side effects like musculoskeletal pain, neurological symptoms, fatigue, and hot flushes (p<0.001). Additionally, adherence varied with treatment duration, with shorter periods associated with better adherence.
Conclusions
The study confirms that adherence to OAMs is significantly affected by both the metastatic status and the severity of side effects. It highlights the urgent need for enhanced educational and management strategies tailored to the specific challenges faced by breast cancer patients, especially those dealing with severe side effects. Ongoing research should focus on developing and testing targeted interventions to improve adherence in these patient groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Institute, Cairo University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
373P - Quality-of-life outcomes in patients with HER2-positive, locally advanced or metastatic breast cancer treated with eribulin mesylate in combination with trastuzumab and pertuzumab in the phase III JBCRG-M06/EMERALD study
Presenter: Norikazu Masuda
Session: Poster session 15
Resources:
Abstract
374P - Real-world (Rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France and Germany
Presenter: Mario Campone
Session: Poster session 15
Resources:
Abstract
375P - Results from the Danish Breast Cancer Group's (DBCG) NAME-trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic breast cancer
Presenter: Anne Sofie Brems-Eskildsen
Session: Poster session 15
Resources:
Abstract
377P - Phase II study of trifluridine/tipiracil in pre-treated patients with ER-positive, HER2-negative metastatic breast cancer: A Dutch BOOG (2019-01 TIBET) study
Presenter: Niels Guchelaar
Session: Poster session 15
Resources:
Abstract
378P - Updated data on real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab
Presenter: Duan Yang
Session: Poster session 15
Resources:
Abstract
379P - Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic breast cancer: A multicentre international retrospective cohort study
Presenter: Luca Visani
Session: Poster session 15
Resources:
Abstract
380P - Assessing interstitial lung disease (ILD) risk in metastatic breast cancer (MBC): A comprehensive meta and network analysis of antibody-drug conjugates (ADCs) compared to available treatment options beyond first-line (1L)
Presenter: Linda Cucciniello
Session: Poster session 15
Resources:
Abstract
381P - Treatment rechallenge after grade 1 trastuzumab-deruxtecan related interstitial lung disease: A real-world experience
Presenter: Kelsey Natsuhara
Session: Poster session 15
Resources:
Abstract
382P - Pyrotinib combined with metronomic oral etoposide (VP-16) in heavily pretreated HER2-positive metastatic breast cancer: A single-arm, phase II study
Presenter: Jiaxuan Liu
Session: Poster session 15
Resources:
Abstract
383P - Clinical experience with TTX-MC138: A first-in-class therapy against metastatic cancer
Presenter: Andreas Varkaris
Session: Poster session 15
Resources:
Abstract